Company Description
Cara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States.
The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.
It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica.
The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea.
Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.
| Country | United States |
| Founded | 2004 |
| IPO Date | Jan 31, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 55 |
| CEO | Christopher Posner |
Contact Details
Address: 400 Atlantic Street, Suite 500 Stamford, Connecticut 06901 United States | |
| Phone | 203 406 3700 |
| Website | caratherapeutics.com |
Stock Details
| Ticker Symbol | CARA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001346830 |
| CUSIP Number | 140755109 |
| ISIN Number | US1407551092 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Christopher A. Posner | President, Chief Executive Officer and Director |
| Ryan D. Maynard | Chief Financial Officer |
| Dr. Derek T. Chalmers D.Sc., Ph.D. | Co-Founder and Senior Advisor |
| Matthew Murphy | Manager of Investor Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 20, 2024 | 425 | Filing |
| Dec 20, 2024 | 8-K/A | [Amend] Current report |
| Dec 18, 2024 | SCHEDULE 13D/A | Filing |
| Dec 18, 2024 | S-4 | Filing |
| Dec 18, 2024 | 425 | Filing |
| Dec 18, 2024 | 8-K | Current Report |
| Nov 22, 2024 | 8-K | Current Report |
| Nov 14, 2024 | 10-Q | Quarterly Report |
| Oct 30, 2024 | SC 13D | General statement of acquisition of beneficial ownership |
| Aug 14, 2024 | 10-Q | Quarterly Report |